New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2014
07:57 EDTRLYPRelypsa price target raised to $41 from $25 at Stifel
Stifel believes that recent data emphasizes the primary role of Relypsa's patiromer in treating patients following the initial abatement of hyperkalemia, and it expects doctors to be impressed by the data. Stifel now expects Relypsa to launch a partnership in Europe and collect 45% royalties there starting in FY17. It keeps a Buy rating on the shares.
News For RLYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
07:26 EDTRLYPBMO Capital specialty pharma analyst holds analyst/industry conference call
Specialty Pharmaceuticals Analyst Maris, along with Dr. Kosiborod, Cardiologist, St. Luke's Mid-America Heart Institute discuss limitations of current standard of care and innovative new treatments for Hyperkalemia, including ZS Pharma’s ZS-9 and Relypsa’s Patiromer on an Analyst/Industry conference call to be held on April 27 at 11 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use